Merck Manual

Please confirm that you are a health care professional

Loading

Approach to the Patient With a Sleep or Wakefulness Disorder

By

Richard J. Schwab

, MD, University of Pennsylvania, Division of Sleep Medicine

Last full review/revision Jun 2020| Content last modified Jun 2020
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Topic Resources

Almost half of all people in the US report sleep-related problems. Disordered sleep can cause emotional disturbance, memory difficulty, poor motor skills, decreased work efficiency, and increased risk of traffic accidents. It can even contribute to cardiovascular disorders and mortality.

The most commonly reported sleep-related symptoms are insomnia and excessive daytime sleepiness (EDS).

  • Insomnia is difficulty falling or staying asleep, early awakening, or a sensation of unrefreshing sleep.

  • EDS is the tendency to fall asleep during normal waking hours.

EDS is not a disorder but a symptom of various sleep-related disorders. Insomnia can be a disorder, even if it exists in the context of other disorders, or can be a symptom of other disorders.

Parasomnias are abnormal sleep-related events (eg, night terrors, sleepwalking).

Pathophysiology

There are 2 states of sleep, each marked by characteristic physiologic changes:

  • Nonrapid eye movement (NREM): NREM sleep constitutes about 75 to 80% of total sleep time in adults. Heart rate and body temperature tend to decrease. NREM sleep consists of 3 stages (N1 to N3) in increasing depth of sleep. Slow, rolling eye movements, which characterize quiet wakefulness and early stage N1 sleep, disappear in deeper sleep stages. Muscle activity also decreases. Stage 2 sleep is characterized by K complexes and sleep spindles on the EEG (see figure Nonrapid eye movement [NREM] EEG). Stage N3 is referred to as deep sleep because arousal threshold is high; people may perceive this stage as high-quality sleep.

  • Rapid eye movement (REM): REM sleep follows each cycle of NREM sleep. It is characterized by low-voltage fast activity on the EEG and postural muscle atonia. Respiration rate and depth fluctuate dramatically. Most dreams occur during REM sleep. Normally, 20 to 25% of sleep is REM.

Progression through the 3 stages, typically followed by a brief interval of REM sleep, occurs cyclically 5 to 6 times a night (see figure Typical sleep pattern in young adults). Brief periods of wakefulness (stage W) occur periodically.

Nonrapid eye movement (NREM) EEG

These EEG tracings show characteristic theta waves, sleep spindles, and K complexes during stages 1 (N1), 2 (N2), and 3 (N3) NREM sleep.

Nonrapid eye movement (NREM) EEG

Rapid eye movement (REM) EEG

This figure includes an EEG tracing (showing characteristic sawtooth waves) and an eye tracing (showing rapid eye movements), which occur during REM sleep.

Rapid eye movement (REM) EEG

Individual sleep requirements vary widely, ranging from 6 to 10 hours/24 hours. Infants sleep a large part of the day; with aging, total sleep time and deep sleep tend to decrease, and sleep becomes more interrupted. In older people, stage N3 may disappear. These changes may account for increasing EDS and fatigue with aging, but their clinical significance is unclear.

Typical sleep pattern in young adults

Rapid eye movement (REM) sleep occurs cyclically throughout the night every 90–120 minutes. Brief periods of wakefulness (stage W) occur periodically. In adults, sleep time is most typically spent as follows:

  • Stage N1: 2–5%

  • Stage N2: 45–55%

  • Stage N3: 13–23%

  • REM: 20–25%

Typical sleep pattern in young adults

Etiology

Some disorders can cause either insomnia or EDS (and sometimes both), and some cause only one or the other (see table Some Causes of Insomnia and Excessive Daytime Sleepiness).

Table
icon

Some Causes of Insomnia and Excessive Daytime Sleepiness

Disorder

Insomnia

Excessive Daytime Sleepiness

Drug-dependent and drug-induced sleep disorders

Inadequate sleep hygiene

= commonly present (but insomnia and/or excessive daytime sleepiness can occur in any of these disorders).

Insomnia is most often caused by

  • An insomnia disorder (eg, adjustment sleep disorder, psychophysiologic insomnia)

  • Inadequate sleep hygiene

  • Psychiatric disorders, particularly mood, anxiety, and substance use disorders

  • Miscellaneous medical disorders such as cardiopulmonary disorders, musculoskeletal conditions, and chronic pain

EDS is most often caused by

Inadequate sleep hygiene refers to behaviors that are not conducive to sleep. They include

  • Consumption of caffeine or sympathomimetic or other stimulant drugs (typically near bedtime, but even in the afternoon for people who are particularly sensitive)

  • Exercise or excitement (eg, a thrilling television show) late in the evening

  • An irregular sleep-wake schedule

Patients who compensate for lost sleep by sleeping late or by napping further fragment their nocturnal sleep.

Adjustment insomnia results from acute emotional stressors (eg, job loss, hospitalization) that disrupt sleep.

Psychophysiologic insomnia is insomnia (regardless of cause) that persists well beyond resolution of precipitating factors, usually because patients feel anticipatory anxiety about the prospect of another sleepless night followed by another day of fatigue. Typically, patients spend hours in bed focusing on and brooding about their sleeplessness, and they have greater difficulty falling asleep in their own bedroom than falling asleep away from home.

Physical disorders that cause pain or discomfort (eg, arthritis, cancer, herniated disks), particularly those that worsen with movement, can cause transient awakenings and poor sleep quality. Nocturnal seizures can also interfere with sleep.

Most major mental disorders are associated with EDS and insomnia. About 80% of patients with major depression report EDS and insomnia; conversely, 40% of chronic insomniacs have a major mental disorder, most commonly a mood disorder.

Insufficient sleep syndrome involves not sleeping enough at night despite adequate opportunity to do so, typically because of various social or employment commitments.

Drug-related sleep disorders result from chronic use of or withdrawal from various drugs (see table Some Drugs That Interfere With Sleep).

Table
icon

Some Drugs That Interfere With Sleep

Cause

Example

Drug use

Alcohol

Antiseizure drugs (eg, phenytoin)

Antimetabolite chemotherapy

Certain antidepressants of the SSRI, SNRI, MAOI, and TCA classes

CNS stimulants (eg, amphetamines, caffeine)

Oral contraceptives

Propranolol

Steroids (anabolic steroids, corticosteroids)

Thyroid hormone preparations

Drug withdrawal

Alcohol

Certain antidepressants of the SSRI, SNRI, MAOI, and TCA classes

CNS depressants (eg, barbiturates, opioids, sedatives)

Illicit drugs (eg, cocaine, heroin, marijuana, phencyclidine)

CNS = central nervous system; MAOI = monoamine oxidase inhibitor; SNRI = serotonin-norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.

Circadian rhythm sleep disorders result in misalignment between endogenous sleep-wake rhythms and environmental light-darkness cycle. The cause may be external (eg, jet lag disorder, shift work disorder) or internal (eg, delayed or advanced sleep phase disorder).

Central sleep apnea consists of repeated episodes of breathing cessation or shallow breathing during sleep, lasting at least 10 seconds and caused by diminished respiratory effort. The disorder typically manifests as insomnia or as disturbed and unrefreshing sleep.

Obstructive sleep apnea consists of episodes of partial or complete closure of the upper airway during sleep, leading to cessation of breathing for ≥ 10 seconds. Most patients snore, and sometimes patients awaken, gasping. These episodes disrupt sleep and result in a feeling of unrefreshing sleep and EDS.

Narcolepsy is characterized by chronic EDS, often with cataplexy, sleep paralysis, and hypnagogic or hypnopompic hallucinations:

  • Cataplexy is momentary muscular weakness or paralysis without loss of consciousness that is evoked by sudden emotional reactions (eg, laughter, anger, fear, joy, surprise). Weakness may be confined to the limbs (eg, patients may drop the rod when a fish strikes their line) or may cause a limp fall during hearty laughter (as in “weak with laughter”) or sudden anger. Cataplexy can also manifest as blurred vision or slurred speech.

  • Sleep paralysis is the momentary inability to move when just falling asleep or immediately after awakening.

  • Hypnagogic and hypnopompic phenomena are vivid auditory or visual illusions or hallucinations that occur when just falling asleep (hypnagogic) or, less often, immediately after awakening (hypnopompic).

Periodic limb movement disorder is characterized by repetitive (usually every 20 to 40 seconds) twitching or kicking of the lower extremities during sleep. Patients usually complain of interrupted nocturnal sleep or EDS. They are typically unaware of the movements and brief arousals that follow, and they have no abnormal sensations in the extremities.

Restless legs syndrome is characterized by an irresistible urge to move the legs and, less frequently, the arms, usually accompanied by paresthesias (eg, creeping or crawling sensations) in the limbs when reclining. To relieve symptoms, patients move the affected extremity by stretching, kicking, or walking. As a result, they have difficulty falling asleep, repeated nocturnal awakenings, or both.

Evaluation

History

History of present illness should include duration and age at onset of symptoms and any events (eg, a life or work change, new drug, new medical disorder) that coincided with onset. Symptoms during sleeping and waking hours should be noted.

The quality and quantity of sleep are identified by determining

  • Bedtime

  • Latency of sleep (time from bedtime to falling asleep)

  • Number and time of awakenings

  • Final morning awakening and arising times

  • Frequency and duration of naps

  • Quality of sleep (whether it is refreshing)

Having patients keep a sleep log for several weeks is more accurate than questioning them. Bedtime events (eg, food or alcohol consumption, physical or mental activity) should be evaluated. Intake of and withdrawal from drugs, alcohol, caffeine, and nicotine as well as level and timing of physical activity should also be included.

If excessive daytime sleepiness is the problem, severity should be quantified based on the propensity for falling asleep in different situations (eg, resting comfortably versus when driving a car). The Epworth Sleepiness Scale may be used; a cumulative score 10 represents excessive daytime sleepiness.

Table
icon

Epworth Sleepiness Scale

Situation

Sitting and reading

Watching television

Sitting inactive in a public place

Riding as a car passenger for 1 hour continuously

Lying down to rest in the afternoon

Sitting and talking to someone

Sitting quietly after lunch (no alcohol)

Sitting in a car stopped for a few minutes in traffic

For each situation, probability of dozing is self-rated as none (0), slight (1), moderate (2), or high (3). A score of 10 suggests daytime sleepiness.

Review of systems should check for symptoms of specific sleep disorders, including

Bed partners or other family members can best identify some of these symptoms.

Past medical history should check for known disorders that can interfere with sleep, including chronic obstructive pulmonary disease (COPD), asthma, heart failure, hyperthyroidism, gastroesophageal reflux, neurologic disorders (particularly movement and degenerative disorders), and painful disorders (eg, rheumatoid arthritis). Risk factors for obstructive sleep apnea include obesity, heart disorders, hypertension, stroke, smoking, snoring, and nasal trauma. Drug history should include questions about use of any drugs associated with sleep disturbance (see table Some Drugs That Interfere With Sleep).

Physical examination

The physical examination is useful mainly for identifying signs associated with obstructive sleep apnea:

  • Obesity with fat distributed around the neck or midriff

  • Large neck circumference (≥ 43.2 cm [17 in] in males, ≥ 40.6 cm [16 in] in females)

  • Mandibular hypoplasia and retrognathia

  • Nasal obstruction

  • Enlarged tonsils, tongue, uvula, or soft palate (modified Mallampati score 3 or 4—see figure Modified Mallampati scoring)

  • Decreased pharyngeal patency

  • Increased obstruction of uvula and soft palate by the tongue

  • Redundant lateral pharyngeal mucosa

Modified Mallampati scoring

Modified Mallampati scoring is as follows:

  • Class 1: Tonsils, uvula, and soft palate are fully visible.

  • Class 2: Hard and soft palate, upper portion of tonsils, and uvula are visible.

  • Class 3: Soft and hard palate and base of the uvula are visible.

  • Class 4: Only the hard palate is visible.

Modified Mallampati scoring

The chest should be examined for expiratory wheezes and kyphoscoliosis. Signs of right ventricular failure, including lower-extremity edema, should be noted. A thorough neurologic examination should be done.

Red flags

The following findings are of particular concern:

  • Falling asleep while driving or other potentially dangerous situations

  • Repeated sleep attacks (falling asleep without warning)

  • Breathing interruptions or awakening with gasping reported by bed partner

  • Unstable cardiac or pulmonary status

  • Recent stroke

  • Status cataplecticus (continuous cataplexy attacks)

  • History of violent behaviors or injury to self or others during asleep

  • Frequent sleepwalking or other out-of-bed behavior

Interpretation of findings

Inadequate sleep hygiene and situational stressors are usually apparent in the history. EDS that disappears when sleep time is increased (eg, on weekends or vacations) suggests inadequate sleep syndrome. EDS that is accompanied by cataplexy, hypnagogic/hypnopompic hallucinations, or sleep paralysis suggests narcolepsy.

Difficulty falling asleep (sleep-onset insomnia) should be distinguished from difficulty maintaining sleep and early awakening (sleep maintenance insomnia).

Sleep-onset insomnia suggests delayed sleep phase syndrome, chronic psychophysiologic insomnia, restless legs syndrome, or childhood phobias.

Falling asleep early and awakening early suggest advanced sleep phase syndrome.

Clinicians should suspect obstructive sleep apnea in patients with significant snoring, frequent awakenings, and other risk factors. The STOP-BANG score can help predict risk of obstructive sleep apnea (see table STOP-BANG Risk Score for Obstructive Sleep Apnea).

Table
icon

STOP-BANG Risk Score for Obstructive Sleep Apnea

Item Evaluated

Finding

Snoring

Loud snoring (louder than talking or loud enough to be heard through a closed door)

Tired

Often fatigue or sleepiness during the daytime

Observed

Observed to stop breathing during sleep

BP

High blood pressure or current treatment for hypertension

BMI

> 35 kg/m2

Age

> 50 years

Neck circumference

> 40 cm (> 15 3/4 in)

Gender

Male

≥ 3 or 4 findings = high risk of OSA.

< 3 findings = low risk of OSA.

BMI = body mass index; OSA = obstructive sleep apnea.

Testing

Tests are usually done when specific symptoms or signs suggest obstructive sleep apnea, nocturnal seizures, narcolepsy, periodic limb movement disorder, or other disorders whose diagnosis relies on identification of characteristic polysomnographic findings. Tests are also done when the clinical diagnosis is in doubt or when response to initial presumptive treatment is inadequate. If symptoms or signs strongly suggest certain causes (eg, restless legs syndrome, poor sleep habits, transient stress, shift work disorder), testing is not required.

Polysomnography is particularly useful when obstructive sleep apnea, narcolepsy, nocturnal seizures, periodic limb movement disorder, or parasomnias are suspected. It also helps clinicians evaluate violent and potentially injurious sleep-related behaviors. It monitors brain activity (via EEG), eye movements, heart rate, respirations, oxygen saturation, and muscle tone and activity during sleep. Video recording may be used to identify abnormal movements during sleep. Polysomnography is typically done in a sleep laboratory; home sleep studies are now commonly used to diagnose obstructive sleep apnea, but not any other sleep disorders (1).

The multiple sleep latency test assesses speed of sleep onset in 5 daytime nap opportunities 2 hours apart during the patient’s typical daytime. Patients lie in a darkened room and are asked to sleep. Onset and stage of sleep (including REM) are monitored by polysomnography to determine the degree of sleepiness. This test’s main use is in the diagnosis of narcolepsy.

For the maintenance of wakefulness test, patients are asked to stay awake in a quiet room during 4 wakefulness opportunities 2 hours apart while they sit in a bed or a recliner. This test is probably a more accurate measure of ability to remain awake in everyday situations.

Patients with EDS may require laboratory tests of renal, liver, and thyroid function.

Evaluation reference

  • 1. Rosen IM, Kirsch DB, Chervin RD, et al: Clinical Use of a Home Sleep Apnea Test: An American Academy of Sleep Medicine Position Statement. J Clin Sleep Med 13 (10):1205–1207, 2017. doi: 10.5664/jcsm.6774.

Treatment

Specific conditions are treated. The primary treatment for insomnia is cognitive-behavioral therapy, which ideally should be done before hypnotics are prescribed. Good sleep hygiene is a component of cognitive-behavioral therapy that is important whatever the cause and is often the only treatment patients with mild problems need.

Cognitive-behavioral therapy

Cognitive-behavioral therapy for insomnia focuses on managing the common thoughts, worries, and behaviors that interfere with sleep. It is typically done in 4 to 8 individual or group sessions but can be done remotely online or by telephone; however, evidence for the effectiveness of remote therapy is weaker.

Cognitive-behavioral therapy for insomnia consists of the following:

  • Helping patients improve sleep hygiene, particularly restricting time spent in bed, establishing a regular sleep schedule, and controlling stimuli

  • Teaching patients about the effects of sleeplessness and helping them identify inappropriate expectations about how much sleep they should get

  • Teaching patients relaxation techniques

  • Using other cognitive therapy techniques as needed

Restricting the amount of time spent in bed aims to limit the time patients spend lying in bed trying unsuccessfully to sleep. Initially, time in bed is limited to the average nightly total sleep time, but not to < 5.5 hours. Patients are asked to get out of bed in the morning at a fixed time and then calculate a bed time based on total sleep time. After a week, this approach typically improves quality of sleep. Then, the time spent in bed can be increased by gradually making bed time earlier, as long as awakenings in the middle of the night remain minimal.

Table
icon

Sleep Hygiene

Measure

Implementation

Regular sleep/wake schedule

Bedtime and particularly wake-up time should be the same each day, including weekends. Patients should not spend excessive time in bed.

Appropriate use of the bed

Limiting time in bed improves sleep continuity. If unable to fall sleep within 20 minutes, patients should get out of bed and return when sleepy. The bed should not be used for activities other than sleep or sex (eg, not for reading, eating, watching television, or paying bills).

Avoidance of daytime naps, except by shift workers, older people, and patients with narcolepsy

Daytime naps may aggravate sleeplessness in patients with insomnia. However, naps decrease the need for stimulants in patients with narcolepsy and improve performance in shift workers. Naps should be taken at the same time each day and limited to 30 minutes.

Regular routine before bedtime

A pattern of activities—brushing teeth, washing, setting the alarm clock—can set the mood for sleep. Bright lights should be avoided before bedtime and during nocturnal awakenings.

Sleep-conducive environment

The bedroom should be dark, quiet, and reasonably cool; it should be used only for sleep and sexual activity. Heavy curtains or a sleep mask can eliminate light, and earplugs, fans, or white-noise devices can help eliminate disturbing noise.

Pillows

Pillows between the knees or under the waist can increase comfort. For patients with back problems, helpful positions include lying supine with a large pillow under the knees and sleeping on one side with a pillow between the knees.

Regular exercise

Exercise promotes sleep and reduces stress, but if done in the late evening, it can stimulate the nervous system and interfere with falling asleep.

Relaxation

Stress and worry interfere with sleep. Reading or taking a warm bath before bedtime can aid relaxation. Techniques such as visual imagery, progressive muscle relaxation, and breathing exercises can be used. Patients should not watch the clock.

Avoidance of stimulants and diuretics

Drinking alcoholic or caffeinated beverages, smoking, eating caffeinated foods (eg, chocolate), and taking appetite suppressants or prescription diuretics—especially near bedtime—should be avoided.

Bright light exposure while awake

Light exposure during the day can help rectify circadian rhythms, but if light exposure is too close to bedtime, it can interfere with sleep. Not using devices that have blue light (eg, phones, televisions, computer screens) a few hours before bedtime is recommended.

Hypnotics

General guidelines for use of hypnotics (see table Guidelines for the Use of Hypnotics) aim at minimizing abuse, misuse, and addiction.

Table
icon

Guidelines for the Use of Hypnotics

Define a clear indication and treatment goal.

Prescribe the lowest effective dose.

Except for specific hypnotics and patients, limit duration of use to a few weeks.

Individualize the dose for each patient.

Use lower doses in patients also taking a central nervous system depressant, in older people, and in patients with hepatic or renal disorders.

Avoid* if patients have sleep apnea or respiratory disorders or a history of sedative abuse, if they are drinking alcohol, or if they are pregnant.

For patients who need longer-term treatment, consider intermittent therapy.

Avoid abruptly stopping the drug if possible (ie, taper it).

Re-evaluate drug treatment regularly; assess efficacy and adverse events.

* Ramelteon is an exception; it can be given to patients with mild to moderate obstructive sleep apnea or chronic obstructive pulmonary disease (COPD) or a history of sedative abuse. Low-dose doxepin also has no abuse liability.

For commonly used hypnotics, see table Oral Hypnotics in Common Use. All hypnotics (except ramelteon, low-dose doxepin, and suvorexant) act at the benzodiazepine recognition site on the gamma-aminobutyric (GABA) receptor and augment the inhibitory effects of GABA.

Hypnotics differ primarily in elimination half-life and onset of action. Drugs with a short half-life are used for sleep-onset insomnia. Drugs with a longer half-life are useful for both sleep-onset and sleep maintenance insomnia, or, in the case of low-dose doxepin, only for sleep maintenance insomnia. Some hypnotics (eg, older benzodiazepines) have greater potential for daytime carryover effects, especially after prolonged use and/or in older people. New drugs with a very short duration of action (eg, low-dose sublingual zolpidem) can be taken in the middle of the night, during a nocturnal awakening, as long as patients stay in bed for at least 4 hours after use.

Patients who experience daytime sedation, incoordination, or other daytime effects should avoid activities requiring alertness (eg, driving), and the dose should be reduced, the drug stopped, or, if needed, another drug used. Other adverse effects include amnesia, hallucinations, incoordination, and falls. Falling is a significant risk with all hypnotics.

Table
icon

Oral Hypnotics in Common Use

Drug

Half Life* (hours)

Dose†

Comments

Benzodiazepine receptor agonists: Benzodiazepines

Triazolam

1.5−5.5

0.25–0.5 mg

May cause anterograde amnesia; high likelihood of tolerance and rebound after repeated use

Temazepam

9.5–12.4

7.5–15 mg

Longest latency for sleep induction

Estazolam

10–24

0.5–2 mg

Effective for sleep induction and maintenance

Quazepam

39–100

7.5–15 mg

High lipophilicity, which may mitigate residual sedation in first 7–10 days of continuous use

Flurazepam

47–100

15–30 mg

High risk of next-day residual sedation; not recommended for older people

Benzodiazepine receptor agonists: Nonbenzodiazepines

Zaleplon

1

5–20 mg

Ultrashort-acting; can be given for sleep-onset insomnia or after nocturnal awakening (if patients can spend at least 4 hours in bed after taking the drug)

When given at normal bedtime, least likely to have residual effects

Zolpidem, tablets

2.5

Men: 5–10 mg

Women: 5 mg

Effective for sleep-onset insomnia only

Zolpidem oral spray‡

2.7

Men: 5 mg, 10 mg

Women: 5 mg

Used for sleep-onset insomnia

Zolpidem, extended-release

2.8

Men: 6.25–12.5 mg

Women: 6.25 mg

Effective for sleep-onset insomnia and sleep maintenance insomnia; no tolerance with up to 6 months of use 3 to 7 nights/week

Zolpidem, sublingual‡

2.9

At bedtime

  • Men: 5 mg, 10 mg

  • Women: 5 mg

Middle of the night

  • Men: 3.5 mg

  • Women: 1.75 mg

More rapid onset of action than zolpidem tablets

Higher doses used for sleep-onset insomnia

Lower doses used for early awakening (should not be taken unless patients can spend at least 4 hours in bed after taking the drug)

Eszopiclone

6

1–3 mg

Effective for sleep-onset insomnia and sleep maintenance insomnia; no tolerance with up to 6 months nightly use

Melatonin receptor agonists

Tasimelteon

0.9–1.7

20 mg

Can increase nighttime sleep duration and decrease daytime sleep duration in totally blind patients who have non–24-hour sleep-wake syndrome

Can cause headaches and abnormal dreams or nightmares (most common adverse effects); no apparent abuse liability

Ramelteon

1–5

8 mg

Useful only for sleep-onset insomnia; one of a few hypnotics that are not associated with abuse liability

Can be safely given to patients with mild to moderate obstructive sleep apnea or chronic obstructive pulmonary disease (COPD)

No difficulties with long-term use

Orexin receptor antagonist

Suvorexant

12

10–20 mg (usual dose: 10 mg once a day within 30 minutes of bedtime; maximum dose: 20 mg)

Useful for sleep-onset insomnia

Use lowest effective dose; may be increased to a maximum of 20 mg once a day if the 10-mg dose is well-tolerated but not effective

Tricyclic antidepressants

Doxepin, ultra low dose

15.3

3 mg, 6 mg

Indicated for sleep maintenance insomnia; no abuse liability

* Includes parent and active metabolites. Arranged in order from shortest to longest half-life.

† Dose given at bedtime.

‡ Newer forms of zolpidem.

Suvorexant is a newer treatment for sleep-onset insomnia that acts by blocking brain orexin receptors, thereby blocking orexin-induced wakefulness signals and enabling sleep initiation. Recommended dose is 10 mg, taken no more than once a night and taken within 30 minutes of going to bed, with at least 7 hours before the planned time of awakening. The dose can be increased but should not to exceed 20 mg once a day. The most common adverse effect is somnolence.

Hypnotics should be used cautiously in patients with pulmonary insufficiency. In older patients, any hypnotic, even in small doses, can cause restlessness, excitement, falls, or exacerbation of delirium and dementia. Rarely, hypnotics can cause complex sleep-related behaviors, such as sleepwalking and even sleep driving; use of higher-than-recommended doses and concurrent consumption of alcoholic beverages may increase risk of such behaviors. Rarely, severe allergic reactions occur.

Prolonged use of hypnotics is typically discouraged because tolerance can develop and because abrupt discontinuation can cause rebound insomnia or even anxiety, tremor, and seizures. These effects are more common with benzodiazepines (particularly triazolam) and less common with nonbenzodiazepines. Difficulties can be minimized by using the lowest effective dose for brief periods and by tapering the dose before stopping the drug (see also Withdrawal and detoxification).

Other sedatives

Many drugs not specifically indicated for insomnia are used to induce and maintain sleep.

Alcohol is used by many patients to help with sleep, but alcohol is a poor choice because after prolonged use and at higher doses, it produces unrefreshing, disturbed sleep with frequent nocturnal awakenings, often increasing daytime sleepiness. Alcohol can further impair respiration during sleep in patients with obstructive sleep apnea and other pulmonary disorders such as chronic obstructive pulmonary disease (COPD).

Over-the-counter (OTC) antihistamines (eg, doxylamine, diphenhydramine) can induce sleep. However, efficacy is unpredictable, and these drugs have long a half-life and have adverse effects such as daytime sedation, confusion, urinary retention, and other systemic anticholinergic effects, which are particularly worrisome in older people.

Antidepressants taken in low doses at bedtime (eg, doxepin 25 to 50 mg, paroxetine 5 to 20 mg, trazodone 50 mg, trimipramine 75 to 200 mg) may improve sleep. However, antidepressants should be used in these low doses mainly when standard hypnotics are not tolerated (rare) or in higher (antidepressant) doses when depression is present. Ultra low dose doxepin (3 or 6 mg) is indicated for sleep maintenance insomnia.

Melatonin is a hormone that is secreted by the pineal gland (and that occurs naturally in some foods). Darkness stimulates secretion, and light inhibits it. By binding with melatonin receptors in the suprachiasmatic nucleus, melatonin mediates circadian rhythms, especially during physiologic sleep onset. Oral melatonin (typically 0.5 to 5 mg at bedtime) may be effective for sleep problems due to delayed sleep phase syndrome. When used to treat this disorder, it must be taken at the appropriate time (a few hours before the evening increase in endogenous melatonin secretion—in early evening for most people, typically 3 to 5 hours before the intended bedtime) and at a low dose of 0.5 to 1 mg; taken at the wrong time, it can aggravate sleep problems. For other forms of insomnia, melatonin's efficacy is largely unproved. Nevertheless, worrisome adverse effects have not been reported after widespread use. Available preparations of melatonin are unregulated, so content and purity cannot be ensured, and the effects of long-term use are unknown.

Key Points

  • Poor sleep hygiene and situational disruptors (eg, shift work, emotional stressors) cause many cases of insomnia.

  • Consider medical disorders (eg, sleep apnea syndromes, pain disorders) and psychiatric disorders (eg, mood disorders) as possible causes.

  • Usually, consider sleep studies (eg, polysomnography) when sleep apnea syndromes, periodic limb movements, or other sleep disorders are suspected, when the clinical diagnosis is in doubt, or when response to initial presumptive treatment is inadequate.

  • Good sleep hygiene, sometimes as part of cognitive-behavioral therapy, is first-line treatment.

  • Use hypnotics and sedatives with caution, especially in older people.

Drugs Mentioned In This Article

Drug Name Select Trade
No US trade name
LEVOPHED
Trimipramine
LUNESTA
INDERAL
PAXIL
Suvorexant
No US brand name
UNISOM
OLEPTRO
ROZEREM
HALCION
DILANTIN
RESTORIL
AMBIEN
DORAL
COMMIT, NICORETTE, NICOTROL
SONATA
ZONALON
Click here for Patient Education
NOTE: This is the Professional Version. CONSUMERS: Click here for the Consumer Version
Professionals also read

Also of Interest

Videos

View All
How to do the Cranial Nerve Examination
Video
How to do the Cranial Nerve Examination
3D Models
View All
Nerve Impulse
3D Model
Nerve Impulse

SOCIAL MEDIA

TOP